Rishi Rattan1, Casey J Allen1, Robert G Sawyer2, Reza Askari3, Kaysie L Banton4, Jeffrey A Claridge5, Christine S Cocanour6, Raul Coimbra7, Charles H Cook8, Joseph Cuschieri9, E Patchen Dellinger10, Therese M Duane11, Heather L Evans9, Pamela A Lipsett12, John E Mazuski13, Preston R Miller14, Patrick J O'Neill15, Ori D Rotstein16, Nicholas Namias17. 1. University of Miami Miller School of Medicine, Miami, FL. 2. University of Virginia Health System, Charlottesville, VA. 3. Brigham and Women's Hospital, Boston, MA. 4. University of Minnesota Medical Center, Minneapolis, MN. 5. Case Western Reserve University School of Medicine, Cleveland, OH. 6. University of California Davis, Davis, CA. 7. University of California San Diego, San Diego, CA. 8. Beth Israel Deaconess Medical Center, Boston, MA. 9. University of Washington Harborview Medical Center, Seattle, WA. 10. University of Washington, Seattle, WA. 11. Virginia Commonwealth University, Richmond, VA. 12. Johns Hopkins University School of Medicine, Baltimore, MD. 13. Washington University School of Medicine, St Louis, MO. 14. Wake Forest-Baptist Health, Winston-Salem, NC. 15. Abrazo West Campus, Goodyear, AZ. 16. University of Toronto St Michael's Hospital, Toronto, Ontario, Canada. 17. University of Miami Miller School of Medicine, Miami, FL. Electronic address: nnamias@miami.edu.
Abstract
BACKGROUND: A recent prospective, multicenter, randomized controlled trial found that 4 days of antibiotics after source control of complicated intra-abdominal infections resulted in similar outcomes when compared with longer duration. We hypothesized that the subset of patients presenting with sepsis have similar outcomes when treated with the shorter course of antibiotics. STUDY DESIGN:Patients from the STOP-IT (Study to Optimize Peritoneal Infection Therapy) trial database meeting criteria for sepsis (ie, temperature <36°C or >38°C and a WBC count <4000 cells/mm(3) or >12,000 cells/mm(3)) were analyzed. Patients had been randomized to receive antibiotics until 2 days after the resolution of fever, leukocytosis, and ileus, with a maximum of 10 calendar days of therapy (n = 45), or to receive a fixed short-course of antibiotics for 4 ± 1 calendar days (n = 67). Outcomes included incidence of and time to surgical site infection, recurrent intra-abdominal infection, Clostridium difficile infection, and extra-abdominal infections, as well as hospital days and mortality. RESULTS:One hundred and twelve of the 588 patients in the STOP-IT database met criteria for sepsis and were adherent to the protocol. With regard to short- vs long-course therapy, surgical site infection (11.9% vs 8.9%; p = 0.759), recurrent intra-abdominal infection (11.9% vs 13.3%; p = 1.00), extra-abdominal infection (11.9% vs 8.9%; p = 0.759), hospital days (7.4 ± 5.5 days vs 9.0 ± 7.5 days; p = 0.188), days to recurrent intra-abdominal infection (12.5 ± 6.6 days vs 18.0 ± 8.1 days; p = 0.185), days to extra-abdominal infection (12.6 ± 5.8 days vs 17.3 ± 3.9 days; p = 0.194), and mortality (1.5% vs 0%; p = 1.00) were similar. There were no cases of C difficile infection. Days to surgical site infection (6.9 ± 3.5 days vs 21.3 ± 6.1 days; p < 0.001) were fewer in the 4-day therapy group. CONCLUSIONS: There was no difference in outcomes between short and long-course antimicrobial therapy in patients with complicated intra-abdominal infection presenting with sepsis. Our findings suggest that the presence of systemic illness does not mandate a longer antimicrobial course if source control of complicated intra-abdominal infection is obtained.
RCT Entities:
BACKGROUND: A recent prospective, multicenter, randomized controlled trial found that 4 days of antibiotics after source control of complicated intra-abdominal infections resulted in similar outcomes when compared with longer duration. We hypothesized that the subset of patients presenting with sepsis have similar outcomes when treated with the shorter course of antibiotics. STUDY DESIGN:Patients from the STOP-IT (Study to Optimize Peritoneal Infection Therapy) trial database meeting criteria for sepsis (ie, temperature <36°C or >38°C and a WBC count <4000 cells/mm(3) or >12,000 cells/mm(3)) were analyzed. Patients had been randomized to receive antibiotics until 2 days after the resolution of fever, leukocytosis, and ileus, with a maximum of 10 calendar days of therapy (n = 45), or to receive a fixed short-course of antibiotics for 4 ± 1 calendar days (n = 67). Outcomes included incidence of and time to surgical site infection, recurrent intra-abdominal infection, Clostridium difficileinfection, and extra-abdominal infections, as well as hospital days and mortality. RESULTS: One hundred and twelve of the 588 patients in the STOP-IT database met criteria for sepsis and were adherent to the protocol. With regard to short- vs long-course therapy, surgical site infection (11.9% vs 8.9%; p = 0.759), recurrent intra-abdominal infection (11.9% vs 13.3%; p = 1.00), extra-abdominal infection (11.9% vs 8.9%; p = 0.759), hospital days (7.4 ± 5.5 days vs 9.0 ± 7.5 days; p = 0.188), days to recurrent intra-abdominal infection (12.5 ± 6.6 days vs 18.0 ± 8.1 days; p = 0.185), days to extra-abdominal infection (12.6 ± 5.8 days vs 17.3 ± 3.9 days; p = 0.194), and mortality (1.5% vs 0%; p = 1.00) were similar. There were no cases of C difficile infection. Days to surgical site infection (6.9 ± 3.5 days vs 21.3 ± 6.1 days; p < 0.001) were fewer in the 4-day therapy group. CONCLUSIONS: There was no difference in outcomes between short and long-course antimicrobial therapy in patients with complicated intra-abdominal infection presenting with sepsis. Our findings suggest that the presence of systemic illness does not mandate a longer antimicrobial course if source control of complicated intra-abdominal infection is obtained.
Authors: Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuk Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger Journal: Intensive Care Med Date: 2017-01-18 Impact factor: 17.440
Authors: Christen E Salyer; Christian B Bergmann; Richard S Hotchkiss; Peter A Crisologo; Charles C Caldwell Journal: J Surg Res Date: 2022-02-05 Impact factor: 2.417
Authors: Juri Katchanov; Benno Kreuels; Florian P Maurer; Kai Wöstmann; Johannes Jochum; Christina König; Kariem Seoudy; Holger Rohde; Ansgar W Lohse; Dominic Wichmann; Michael Baehr; Camilla Rothe; Stefan Kluge Journal: BMC Infect Dis Date: 2017-02-08 Impact factor: 3.090
Authors: Omar Nunez Lopez; Janos Cambiaso-Daniel; Ludwik K Branski; William B Norbury; David N Herndon Journal: Ther Clin Risk Manag Date: 2017-08-29 Impact factor: 2.423
Authors: Sylke Haal; Britt Ten Böhmer; Sebastiaan Balkema; Annekatrien Ctm Depla; Paul Fockens; Jeroen M Jansen; Sjoerd D Kuiken; Boris I Liberov; Ellert van Soest; Jeanin E van Hooft; Elske Sieswerda; Rogier P Voermans Journal: United European Gastroenterol J Date: 2020-03-17 Impact factor: 4.623